Since 2008 Arzeda has been harnessing the power of computational and synthetic biology to create new enzymes and chemical products that can compete on performance, cost and sustainability. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of enzymes and specialty chemicals for polymers, advanced materials and health and nutrition products. Arzeda's proprietary platform and validation process rapidly create 'cell factories' that can be used at an industrial scale to solve problems and create opportunities that otherwise would be impossible.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/20/17 | $12,000,000 | Series A |
Bioeconomy Capital OS Fund  Sustainable Conversion Ventures WRF Capital | undisclosed |
| 03/30/22 | $33,000,000 | Series B |
Bioeconomy Capital Bunge Ventures Casdin Capital Circulate Capital Conti Ventures Lewis & Clark Ventures OS Fund UMI | undisclosed |
| 09/17/24 | $38,000,000 | Venture |
Bunge Ventures Continental Grain Fall Line Capital Lewis & Clark Agrifood Silver Blue Sofinnova Partners Sucden Ventures W.L. Gore & Associates | undisclosed |
